Certara, Inc. · NASDAQ:CERT

Certara — Technical Presentation (March 2015)

29 slides from Certara's technical presentation, March 2015

  1. Slide 1: How LC-MS Proteomics Is Revolutionizing PBPK Modelling and Simulation

    How LC-MS Proteomics Is Revolutionizing PBPK Modelling and Simulation Amin Rostami-Hodjegan Professor of Systems Pharmacology University of Manchester, Manchester, UK & Senior Vice President of R&D and Chief Scientific Officer Certara , Princeton, USA amin.rostami@manchester.ac.uk

  2. Slide 2: What is PBPK? Typical View / Nothing New!

    What is PBPK? Typical View / Nothing New! Lung Generic Typical View: Adipose Bone Venous Blood Arterial Blood Brain Describing the C-t Heart profiles based on Kidney physiological Muscle knowledge of the flows Skin and partitions Liver Spleen Portal Vein Gut IV PO Nothing New: Teorell, T. Studies on

  3. Slide 3: What is IVIVE? "New Tricks" for an "Old Hat"

    What is IVIVE? “New Tricks” for an “Old Hat” In Vitro to In Vivo Extrapolation

  4. Slide 4: How PBPK and IVIVE are linked? Sub-Models

    How PBPK and IVIVE are linked? Sub-Models 4Brain Mc KiM (Mechanistic Brain Distribution) Mechanistic Kidney Model ADAM Advanced Dissolution, PerL Absorption, Permeability Metabolism Limited Liver

  5. Slide 5: How LC-MS Proteomics Is Revolutionizing PBPK Modeling and Simulation

    How LC-MS Proteomics Is Revolutionizing PBPK Modeling and Simulation Brahim Achour (MPharm, PhD) Manchester Pharmacy School & Manchester Institute of Biotechnology University of Manchester brahim.achour@manchester.ac.uk

  6. Slide 6: Common LCMS-Related Phrases You Need to Know

    Common LCMS-Related Phrases You Need to Know Targeted proteomics: when a specific protein or set of proteins is quantified These experiments usually use heavy isotope labeled standards (i.e. AQUA, QconCAT, PSAQ) Untargeted proteomics: when the instrument is scanning for all peptides/proteins in the

  7. Slide 7: Course on LCMS Proteomics in One Slide!

    Course 101 on LCMS Proteomics in One Slide! Various Types of LC-MS for Proteomics: AQUA QconCAT PSAQ Label-free Al Feteisi et al., AAPS J, 2015 (In Press); Al Feteisi et al., EODMT, 2015 (Under Review)

  8. Slide 8: Numbers Game: Sample Size vs. Number of Proteins

    Numbers Game: Sample Size vs. Number of Proteins Enzymes/ Global Profiling Transporters Al Feteisi et al., AAPS J, 2015 (In Press)

  9. Slide 9: The Best Method to Buy for You?

    The Best Method to Buy for You? ADME Proteins Choice LC-MS = F (Availability, Application, Cost, Performance) Al Feteisi et al., AAPS J, 2015 (In Press)

  10. Slide 10: Our Specialty in Manchester: What is QconCAT?

    Our Specialty in Manchester: What is QconCAT? A schematic of the QconCAT method Russell et al., J Proteome Res, 2013.

  11. Slide 11: Simultaneous Measurement of SEVERAL Target Proteins

    Simultaneous Measurement of SEVERAL Target Proteins Need for simultaneous quantification of several ADME proteins in a large number of samples Achour et al., DMD, 2014a.

  12. Slide 12: Genetic & Epigenetic Covariates in Expression and Activity

    Genetic & Epigenetic Covariates in Expression and Activity Other factors may include: Genetics • Race • Medical history • Medication • Smoking and drinking Number of livers (n = 24) Age and sex Correlation of expression and with activity Achour et al., DMD, 2014a.

  13. Slide 13: Inter-Correlations: Realistic Virtual Populations

    Inter-Correlations: Realistic Virtual Populations CYP3A5*1/*3 CYP3A5*3/*3 Scarce data for cross-family correlations in the literature (Potential for QconCAT LC-MS!) Confirmed by meta-analyses of available literature [8 studies, n = 137 livers, 5 labs (UGTs); 50 studies, n = 419 livers, 26 labs (CYPs

  14. Slide 14: Example: Enzymes with Equal Contribution to CL

    Example: Enzymes with Equal Contribution to CL (average) fm by Each Enzyme (in an average patient) Enzyme A Enzyme B 500 500 450 450 400 400 350 350 300 300 Enzyme B Enzyme B 250 250 200 200 150 150 100 100 50 50 0 0 0 100 200 300 400 500 0 100 200 300 400 500 Enzyme A Enzyme A

  15. Slide 15: Overprediction (DDI) & Underprediction (CL) of Variability

    Overprediction (DDI) & Underprediction (CL) of Variability Note: Current models do NOT consider ALL correlations between CYPs/UGTs 80 60 Variability in DDI Variability in Clearance (5 Fold for NC; 10 Fold for C) (3 Fold for NC; 2 Fold for C) 70 50 60 Frequency Frequency 40 50 Correlated Correlated N

  16. Slide 16: How about transporters? How about other organs?

    How about transporters? How about other organs? Harwood et al., JPBA, 2015 (Under Review)

  17. Slide 17: Absolute Quantification of Transporters Across Labs

    Absolute Quantification of Transporters Across Labs Good Quality data from across 5 labs Oswald et al., AAPS J, 2013. – No heterogeneity detected! Groer et al., J Pharm Biomed Anal, 2013. Drozdzik et al., Mol Pharm, 2014 UoM = University of Manchester LLQ = lower limit of quantification ; DNQ = Did

  18. Slide 18: How about mRNA? Is it easier?

    How about mRNA? Is it easier? mRNA Protein mRNA Protein mRNA Protein mRNA Protein Donor 1 Donor 2 Donor 3 Donor 4 mRNA and protein expression profiles seem to match! Warhurst, Achour, Harwood, Rostami, 2015 (Not Published)

  19. Slide 19: mRNA for Individualization of Doses?

    mRNA for Individualization of Doses? Good overall correlation (n=16) Good correlation for P-gp, BCRP and OST-β (n=4) Warhurst, Achour, Harwood, Rostami, 2015 (Not Published)

  20. Slide 20: Going from In Vitro to In Vivo? Scaling factors?

    Going from In Vitro to In Vivo? Scaling factors? Example relative expression factors – Different for different transporters! Accounting for losses: Gravimetric method! RF=0.53 RF=0.22 RF=1.67 Harwood, Achour, Warhurst, Rostami, 2014 (Not Published)

  21. Slide 21: How about Scaling Transport in the Liver?

    How about Scaling Transport in the Liver? Scaling factors; protein specific? System specific? Open symbols, liver tissue; gray symbols, SCHH; Black symbols, cryopreserved hepatocytes Badee et al., DMD, 2015 (In Press)

  22. Slide 22: Global Profiling of Drug-Metabolizing Enzymes (DMEs)

    Global Profiling of Drug-Metabolizing Enzymes (DMEs) A) B) C) Enzymes CYPs UGTs Achour, Lanucara, Barber, Rostami, 2015 (Not Published)

  23. Slide 23: Abundance Data for So Called Phase I Enzymes

    Abundance Data for So Called Phase I Enzymes HH01 HH08 HH38 ~50 phase I enzymes HH76

  24. Slide 24: Abundance Data for So Called Phase II Enzymes

    Abundance Data for So Called Phase II Enzymes HH01 HH08 HH38 HH76 ~20 phase II enzymes

  25. Slide 25: How does 'Label Free' Values correlate with 'QconCAT'?

    How does ‘Label Free’ Values correlate with ‘QconCAT’? Targeted data from Achour et al., 2014 Good correlation between untargeted (Label-free) and targeted (QconCAT) methods developed in Manchester: Future trend?

  26. Slide 26: What Next? Where is Proteomics-PBPK Link Going?

    What Next? Where is Proteomics-PBPK Link Going? • Global profiling of ADME proteins (enzymes and transporters) in different organs (individual fingerprint) • Individualized dosing: stratified patient groups (cancer, diabetes, liver/kidney failure) • Use of enzyme expression patterns in blood cells a

  27. Slide 27: Acknowledgements

    Acknowledgements Manchester Pharmacy School Gut Barrier Group, Salford Royal NHS Dr. Jill Barber Trust Hajar Al Feteisi Dr. Geoff Warhurst Prof. Gordon Carlson Institute of Cancer Sciences Dr. Matthew Russell Waters Dr. Francesco Lanucara Protein Expression Facility Dr. Edward Mckenzie Financial and

  28. Slide 28: Next Webinar in the Series

    Next Webinar in the Series How Do We Translate Preclinical and Clinical Research into Drug Labeling? • Wednesday, March 25, 2015 at 11am EST • Karen Rowland Yeo, Sr. Scientific Advisor & Principal Consultant • Description – A validated PBPK model can be used to assist with dose selection in the pres

  29. Slide 29: Contacts & Follow-Up: Thank you!

    Contacts & Follow-Up: Thank you! Americas Telephone (US): 888-708-7444 Telephone (Intl): +1-919-852-4685 Email: sales@certara.com Europe Telephone: +33 1 56 95 17 10 Email: sales@certara.com India Telephone: +91 984 500 6625 Email: sales@certara.com Japan Telephone: +81 (0)50-3786-9898 Email: sales@

Certara — Technical Presentation (March 2015) on 6ix